Shandong Danhong Pharmaceutical Co., Ltd.

D3 Bio (Wuxi) Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.

Shandong Luye Pharmaceutical Co., Ltd.

Cisen Pharmaceutical Co., Ltd.

Guangzhou Joyo Pharmatech Co., Ltd.

Simcere Pharmaceutical Co., Ltd.

Cspc Zhongqi Pharmaceuticall Technology (Shijiazhuang) Co., Ltd.

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory

Shanghai Jia Tan Pharmatech Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology Co., Ltd.

Jikui Sun

Shuhui Chen

Jian Li

Wentao Wu

Yangyang Xu

Jie Li

Haiying He

Jing Zhang

Jianfei Wang

Weihua Shi

Bo Gao

Lei Huang

Zhigan Jiang

Guangwen Yang

Lixia Han

Qiu Li

John Fenyu Jin

Zhijian Chen

Peng Li

Chengde Wu

Tao Yu

Tao Feng

Zhengxia Chen

Zhixiang Li

Huiping Amy Guan

Zhifei Fu

Wei Wang

Miaorong Luo

Yikai Wang

Wenyuan Zhu

Nengyang Shi

Linlin Chen

Kaijun Geng

Rongxin Huang

Deyao Li

Zhihua Ao

Dongling Hao

Yang Zhang

Huiping Guan

Disclosed are a class of compounds having a highly selective inhibition of ROS1, and the use thereof in the preparation of drugs for treating diseases related to abnormal ROS1 kinase expression. Specifically disclosed are compounds represented by formula (IV) and a pharmaceutically acceptable salt thereof.

Compound as highly selective ROS1 inhibitor and use thereof

Disclosed are a series of benzopyrimidine compounds and a use thereof, and specifically disclosed are compounds represented by formula (II) and pharmaceutically acceptable salts thereof.

Benzopyrimidine compounds and use thereof

Disclosed are the solid form, crystalline form, crystal form A of a compound of formula (I), and a preparation method therefor, crystal form B and a preparation method therefor. Also disclosed are use of the solid form, crystalline form, crystal form A, and crystal form B in the preparation of drugs for the treatment of diseases related to FGFR.

FGFR inhibitor compound in solid form and preparation method therefor

A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.

Pyrimidoheterocyclic compounds and application thereof

A compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of medicaments for treating solid tumor-related diseases. 

Pyrazolopyrimidine derivative and use thereof

Provided is a FGFR inhibitor, designating a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Also provided is the application of a drug for treating solid tumors, such as FGFR related diseases. 

Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors

The present invention relates to a series of 2,6-dioxaspiro [4,5] decane derivatives and applications thereof in preparation of opiate receptor &#x3bc; agonist related drugs; and in particular relates to the derivative compounds shown in formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof. 

2,6-dioxaspiro [4,5] decane derivatives and preparation method therefor and pharmaceutical applications thereof

Disclosed are an antiviral compound and a use thereof in the preparation of a medicament for the treatment of virus infections. Specifically, the present invention relates an imidazole derivative for treating respiratory syncytial virus infection.

Imidazole derivative used as antiviral agent and use thereof in preparation of medicament

The present invention relates to novel pyridino[1,2-&#x3b1;]pyrimidone compounds represented by formula (I) or pharmaceutically acceptable salts thereof; and a method of use thereof for treating tumors.

Pyridino[1,2-A]pyrimidone analogue used as MTOR/P13K inhibitor

Imidazole derivative used as antiviral agent and use therof in preparation of medicament

Growing community of inventors

Shanghai, China

Jikui Sun